AM5206

AM5206 is an orally available small molecule developed by MAK Scientific Management, currently in development for neuroprotection. It functions as a modulator of the endocannabinoid system, with its primary characterized mechanism being the neutral antagonism of the Cannabinoid receptor 1 (CB1). Unlike traditional CB1 inverse agonists, neutral antagonists like AM5206 are designed to provide therapeutic effects—such as reducing neuroinflammation and providing neuroprotection—without the significant psychiatric side effects associated with receptor inverse agonism. The compound is part of a broader research program at MAK Scientific that targets various components of the endocannabinoid signaling pathway, including CB2 receptors, fatty acid amide hydrolase (FAAH), and monoacylglycerol lipase (MAGL), to address neurodegenerative and metabolic conditions.